



NEWS RELEASE

## Repligen Corporation to Present at Upcoming Investor Conferences

2021-11-12

WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at two upcoming investor conferences.

- Stifel's 2021 Virtual Healthcare Conference being held November 15-17. Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Wednesday, November 17, at 8:00 a.m. EST.
- Stephens Annual Investment Conference being held December 1-3. Jon K. Snodgres, Chief Financial Officer, will participate in a fireside chat on Friday, December 3, at 11:00 a.m. EST.

A live webcast of the discussions will be accessible through the **Investor Relations** section of the Company's website, and will be available for replay for a limited period of time following the conference event.

### About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Hampshire, New Jersey and New York), and outside of the U.S. we have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at [www.repligen.com](http://www.repligen.com). Follow us on **LinkedIn** and **Twitter**

Repligen Contact:

Sondra S. Newman

Global Head of Investor Relations

(781) 419-1881

[investors@repligen.com](mailto:investors@repligen.com)

Source: Repligen Corporation